MEDIVIR AB – INTERIM REPORT, JANUARY – MARCH 2019
Clinical studies progress according to plan January – MarchSignificant events during the quarter · The phase II study of birinapant in combination with Keytruda® in colorectal cancer patients progresses according to plan. A futility analysis is planned to be conducted no later than the fourth quarter of 2019. · The phase Ia study of MIV-818 in patients with liver cancer is planned to be completed during the second quarter of 2019. · As a result of the restructuring of Medivir, there is no longer any preclinical research conducted in the company. The new organization focuses